Table 2.

Influence of Baseline Kidney Function on Risk (Hazard Ratio (HR) and 95% Confidence Interval (CI)) of Thromboembolism and Hemorrhage

	Hazard Ratio	95 % Confidence Interval	p-value
Thromboembolic Events
Stage of Kidney Disease at Baseline
Stage 1 (eGFR≥90)	ref	Ref	ref
Stage 2 (eGFR 60-89)	0.82	0.23-2.94	0.77
Stage 3a (eGFR 45-59)	1.47	0.47-4.62	0.51
Stage 3b (eGFR 30-44)	1.75	0.55-5.58	0.35
Stage 4 (eGFR 15-29)	1.52	0.41-5.68	0.53
Stage 5 (eGFR <15)	0.94	0.10-8.38	0.95
Hemorrhagic Events
Stage of Kidney Disease at Baseline
Stage 1 (eGFR≥90)	ref	ref	ref
Stage 2 (eGFR 60-89)	1.55	0.56-4.32	0.40
Stage 3a (eGFR 45-59)	1.71	0.63-4.67	0.29
Stage 3b (eGFR 30-44)	2.04	0.73-5.67	0.17
Stage 4 (eGFR 15-29)	0.99	0.26-3.70	0.99
Stage 5 (eGFR <15)	n/a	n/a	n/a
Death
Stage of Kidney Disease at Baseline
Stage 1 (eGFR≥90)	ref	ref	ref
Stage 2 (eGFR 60-89)	1.52	0.48-4.77	0.47
Stage 3a (eGFR 45-59)	2.21	0.74-6.57	0.15
Stage 3b (eGFR 30-44)	3.12	1.16-9.17	0.039
Stage 4 (eGFR 15-29)	3.94	1.29-12.0	0.02
Stage 5 (eGFR <15)	7.24	2.18-24.1	0.0012

Kidney function is presented as CKD stages as recommended by the Kidney Disease Outcomes Quality Initiative guidelines using estimated glomerular filtration rate (eGFR) from the Chronic Kidney Disease Epidemiology Collaboration Formula (CKD-EPI).

The groups are Stage 1 (eGFR≥90 ml/min/1.73m2), Stage 2 (eGFR 60-90 ml/min/1.73m²), Stage 3a (eGRF 45-59 ml/min/1.73m²), Stage 3b (eGFR 30-44 ml/min/1.73m²), Stage 4 (eGFR 15-30 ml/min/1.73m²) and Stage 5 (eGFR<15 ml/min/1.73m²)

Follow-up is calculated as time from VAD to first event or end of study period (1 year or time until explantation/transplantation) for thromboembolic events and hemorrhagic events. Follow-up time for incidence of death is calculated as time to death or end of study period (1 year or explantation/transplantation

Cox proportional hazards models were used to assess the risk of thromboembolism and hemorrhage, and death. The proportional hazards assumption was met.